22q11.2缺失综合征患者物质使用患病率低
这项横断面研究纳入434例22q11.2缺失综合征患者、265例非缺失精神病患者和134例健康对照,比较物质使用情况。结果显示22q11.2缺失综合征患者的总物质使用(36.9%)和物质使用障碍(1.2%)患病率显著低于非缺失精神病患者和健康对照,健康对照使用物质的可能性是22q11.2缺失综合征患者的20倍(P < 0.001)。
要点
- 22q11.2缺失综合征患者物质使用和物质使用障碍患病率显著低于非缺失精神病患者和健康对照。
- 健康对照使用物质的可能性是22q11.2缺失综合征患者的20倍(P < 0.001),酒精和尼古丁分别也显著。
- 22q11.2缺失综合征组内物质使用与精神病或COMT基因型无关,男性患者物质使用可能性高于女性。
核心结论
- 22q11.2缺失综合征患者尽管精神病风险增加,但物质使用和物质使用障碍风险降低。
研究设计与样本
- 横断面研究纳入434例22q11.2缺失综合征患者、265例非缺失精神病患者和134例健康对照。
- 22q11.2缺失综合征组评估精神科诊断、全量表智商和COMT Val158Met基因型,物质使用数据按复合国际诊断访谈收集。
主要发现
- 22q11.2缺失综合征患者总物质使用患病率为36.9%,物质使用障碍患病率为1.2%,每周酒精和尼古丁使用量均显著低于非缺失精神病患者或对照。
- 健康对照使用物质的可能性是22q11.2缺失综合征患者的20倍(P < 0.001),酒精和尼古丁使用分别也显著。
- 22q11.2缺失综合征组内物质使用患病率与精神病或COMT基因型无关。
- 22q11.2缺失综合征男性患者物质使用可能性高于女性患者。
临床怎么用
- 对22q11.2缺失综合征患者进行物质使用评估时,需注意其患病率可能较低,但仍应个体化筛查。
- 男性22q11.2缺失综合征患者物质使用可能性较高,可优先关注。
局限性
- 原文未明确报告局限性。
- 横断面设计无法推断因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 22q11.2 deletion syndrome (22q11DS), one of the most common recurrent copy number variant disorders, is associated with dopaminergic abnormalities and increased risk for psychotic disorders. AIMS: Given the elevated prevalence of substance use and dopaminergic abnormalities in non-deleted patients with psychosis, we investigated the prevalence of substance use in 22q11DS, compared with that in non-deleted patients with psychosis and matched healthy controls. METHOD: This cross-sectional study involved 434 patients with 22q11DS, 265 non-deleted patients with psychosis and 134 healthy controls. Psychiatric diagnosis, full-scale IQ and COMT Val158Met genotype were determined in the 22q11DS group. Substance use data were collected according to the Composite International Diagnostic Interview. RESULTS: The prevalence of total substance use (36.9%) and substance use disorders (1.2%), and weekly amounts of alcohol and nicotine use, in patients with 22q11DS was significantly lower than in non-deleted patients with psychosis or controls. Compared with patients with 22q11DS, healthy controls were 20 times more likely to use substances in general (P < 0.001); results were also significant for alcohol and nicotine use separately. Within the 22q11DS group, there was no relationship between the prevalence of substance use and psychosis or COMT genotype. Male patients with 22q11DS were more likely to use substances than female patients with 22q11DS. CONCLUSIONS: The results suggest that patients with 22q11DS are at decreased risk for substance use and substance use disorders despite the increased risk of psychotic disorders. Further research into neurobiological and environmental factors involved in substance use in 22q11DS is necessary to elucidate the mechanisms involved. DECLARATION OF INTEREST: None.
引用
- Vingerhoets C, van Oudenaren MJF, Bloemen OJN, et al. Low prevalence of substance use in people with 22q11.2 deletion syndrome. Br J Psychiatry. 2019. PMID: 30604657. doi:10.1192/bjp.2018.258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。